{
    "sec_cik": "0000899866",
    "sec_company_name": "ALEXION PHARMACEUTICALS, INC. (Filer)",
    "document_type": "EX991",
    "sec_form_header": "Form 8-K",
    "sec_period_of_report": "20200113",
    "sec_filing_date": "20200113",
    "sec_changed_date": "20200113",
    "sec_accepted_date": "20200113061850",
    "sec_index_url": "https://www.sec.gov//Archives/edgar/data/899866/000089986620000002/0000899866-20-000002-index.htm",
    "sec_url": "https://www.sec.gov//Archives/edgar/data/899866/000089986620000002/0000899866-20-000002.txt",
    "metadata_file_name": "C:\Users\aaron\OneDrive\Desktop\homework\finance2\SEC-EDGAR-text\output_files_examples\batch_0009\003\ALXN_0000899866_EX991_20200113_EX-99_metadata.json",
    "original_file_name": "",
    "original_file_size": "83858 chars",
    "document_group": "EX-99",
    "section_name": "EX-99",
    "section_n_characters": 28285,
    "endpoints": [
        "jpm2020deck11jan2020fbda   ",
        " FOCUS ON RARE DISEASE ASSETS TO EXPAND ADDRESSABLE PATIENT POPULATION 34 | VISION TO 2020 & BEYOND RARE INSPIRATION. CHANGING LIVES. ~60-80,000 Mild/ Rare Moderate >50K ~10,000 ~10,000 ~35,000 Rare <6,000 <6,000 Refractory <6-50K / severe <6,000 Ultra-rare <6K PNH with Wilsonâ€™s AL Other C3G PNH WAIHA gMG clinical EVH disease Amyloidosis Indications FcRN: ACH-4471 ACH-5228 ALXN1840 CAEL-101 ALXN1830, ABY-039"
    ],
    "extraction_method": "html",
    "warnings": [],
    "company_description": "ALXN",
    "output_file": "C:\Users\aaron\OneDrive\Desktop\homework\finance2\SEC-EDGAR-text\output_files_examples\batch_0009\003\ALXN_0000899866_EX991_20200113_EX-99_excerpt.txt",
    "time_elapsed": 0.0,
    "batch_number": 9,
    "batch_signature": "",
    "batch_start_time": "2023-04-16 23:34:09.101264",
    "batch_machine_id": "DESKTOP-BTCJU5K",
    "section_end_time": "2023-04-16 23:42:24.300099"
}